CD8A and urothelial carcinoma: Similarly, patients with advanced urothelial carcinoma (pT2, pT3, or pT4) who had higher numbers of CD8+ TILs (> 8), showed longer disease-free survival (P < 0.001) and OS (P < 0.018) compared to those who had fewer CD8+ TILs [22].